After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
6don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Bristol Myers (BMY) Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY in ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Shares of Bristol Myers Squibb Co. BMY rallied 1.03% to $56.80 Monday, on what proved to be an all-around mixed trading ...
Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback